CA3136831A1 - Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins - Google Patents
Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins Download PDFInfo
- Publication number
- CA3136831A1 CA3136831A1 CA3136831A CA3136831A CA3136831A1 CA 3136831 A1 CA3136831 A1 CA 3136831A1 CA 3136831 A CA3136831 A CA 3136831A CA 3136831 A CA3136831 A CA 3136831A CA 3136831 A1 CA3136831 A1 CA 3136831A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- ecd
- fusion molecules
- concentration
- histidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842722P | 2019-05-03 | 2019-05-03 | |
| US62/842,722 | 2019-05-03 | ||
| PCT/US2020/030946 WO2020227062A1 (en) | 2019-05-03 | 2020-05-01 | Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3136831A1 true CA3136831A1 (en) | 2020-11-12 |
Family
ID=70847527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3136831A Pending CA3136831A1 (en) | 2019-05-03 | 2020-05-01 | Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220227834A1 (https=) |
| EP (1) | EP3963079A1 (https=) |
| JP (1) | JP7716988B2 (https=) |
| AR (1) | AR118853A1 (https=) |
| AU (1) | AU2020270395A1 (https=) |
| CA (1) | CA3136831A1 (https=) |
| MX (1) | MX2021013272A (https=) |
| TW (1) | TW202108126A (https=) |
| WO (1) | WO2020227062A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| WO2026062544A1 (en) * | 2024-09-23 | 2026-03-26 | Pfizer Inc. | Sirp alpha fusion protein formulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| US11306144B2 (en) * | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
-
2020
- 2020-05-01 EP EP20728297.1A patent/EP3963079A1/en active Pending
- 2020-05-01 US US17/608,546 patent/US20220227834A1/en active Pending
- 2020-05-01 WO PCT/US2020/030946 patent/WO2020227062A1/en not_active Ceased
- 2020-05-01 CA CA3136831A patent/CA3136831A1/en active Pending
- 2020-05-01 MX MX2021013272A patent/MX2021013272A/es unknown
- 2020-05-01 JP JP2021564994A patent/JP7716988B2/ja active Active
- 2020-05-01 AU AU2020270395A patent/AU2020270395A1/en active Pending
- 2020-05-04 AR ARP200101262A patent/AR118853A1/es unknown
- 2020-05-04 TW TW109114796A patent/TW202108126A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020227062A1 (en) | 2020-11-12 |
| AU2020270395A1 (en) | 2021-12-23 |
| EP3963079A1 (en) | 2022-03-09 |
| JP2022531387A (ja) | 2022-07-06 |
| AR118853A1 (es) | 2021-11-03 |
| MX2021013272A (es) | 2021-11-17 |
| JP7716988B2 (ja) | 2025-08-01 |
| US20220227834A1 (en) | 2022-07-21 |
| TW202108126A (zh) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12252537B2 (en) | Antibody molecules that bind CD137 and OX40 | |
| JP7756072B2 (ja) | Ｔ細胞調節ポリペプチド及びその使用方法 | |
| CN108367072B (zh) | 含抗-pd-l1抗体avelumab的水性药物制剂 | |
| JP2024037894A (ja) | 抗ｎｋｇ２ａ抗体およびその使用 | |
| CA3136831A1 (en) | Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins | |
| US20190359672A1 (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
| JP5878182B2 (ja) | ミュータントインターロイキン−２ポリペプチド | |
| KR20210089215A (ko) | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 | |
| KR102940517B1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물 | |
| US20230270879A1 (en) | Anti-B7-H4 Antibodies And Methods | |
| CN109715210B (zh) | Cd80和cd86结合蛋白组合物及其用途 | |
| JP2024536932A (ja) | Ｉｌ－２３シグナル伝達を阻害する組成物および方法 | |
| US20240279342A1 (en) | Compositions and methods for immunotherapy | |
| KR20200089282A (ko) | 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도 | |
| KR20190125363A (ko) | 수성 항-pd-l1 항체 제제 | |
| WO2022184067A1 (zh) | 抗tigit抗体在联合用药中的应用 | |
| TW202311293A (zh) | 免疫療法之組合及其用途 | |
| US20230416386A1 (en) | Use of anti-ox40 antibody in treatment of tumor or cancer | |
| CN116134053A (zh) | 用于使用PD-1 x CTLA-4双特异性分子的方法 | |
| JP2024506931A (ja) | Ｄｒ５結合性ポリペプチドの製剤 | |
| JP2023538902A (ja) | 操作されたリガンドを使用する材料及び方法 | |
| CN116745322A (zh) | 使用抗岩藻糖基-gm1抗体的组合疗法 | |
| US20250206801A1 (en) | Cd80 protein variant and cd80 fusion protein | |
| RU2828377C1 (ru) | Фармацевтическая композиция для лечения злокачественной опухоли, содержащая слитый белок, содержащий белок il-2 и белок cd80, и ингибитор иммунной точки контроля | |
| CN114786701B (zh) | 用于治疗癌症的包括包含il-2蛋白和cd80蛋白的融合蛋白和免疫检查点抑制剂的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220913 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250422 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250422 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250613 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250613 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260327 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260421 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260421 |